CONTENTS
• Alcohol harm - the urgent need for a global response. Casswell S., p. 1205-1207.
• Can food be addictive? Public health and policy implications. Gearhardt A.N., Grilo C.M., Dileone R.J., Brownell K.D., Potenza M.N., p. 1208-1212.
• Obesity - is food addiction to blame? Rogers P.J., p. 1213-1214.
• Food and addiction - sugars, fats and hedonic overeating. Avena N.M., Gold M.S., p. 1214-1215.
• Maternal diet and offspring development. Davis C., p. 1215-1216.
• Food addiction not helpful: the hedonic component - implicit wanting - is important. Blundell J.E., Finlayson G., p. 1216-1218.
• All foods are habit-forming - what I want to know is which will kill me! Smith T.G., p. 1218-1219.
• Important next steps in evaluating food's addictive potential. Gearhardt A.N., Dileone R.J., Grilo C.M., Brownell K.D., Potenza M.N., p. 1219-1220.
• Towards a national model for managing impaired driving offenders. Voas R.B., Dupont R.L., Talpins S.K., Shea C.L., p. 1221-1227.
• Commentary on Voas et al. (2011): Drug-free roadways - can we get there from here? Steps to reducing drugged driving in the United States. Gil Kerlikowske R., Sabet K., p. 1228-1229.
• Measuring alcohol craving: development of the Alcohol Craving Experience questionnaire. Statham D.J., Connor J.P., Kavanagh D.J., Feeney G.F., Young R.M., May J., et al., p. 1230-1238.
• Alcohol-related discussions in health care-a population view. Makela P., Havio M., Seppa K., p. 1239-1248.
• Commentary on Makelaet al. (2011): How many patients must be asked about alcohol before it is enough? Spak F., p. 1249-1250.
• The prevalence of alcohol use disorders among night-time weekend drivers. Furr-Holden C.D., Voas R.B., Lacey J., Romano E., Jones K., p. 1251-1260.
• Does readiness to change predict in-session motivational language? Correspondence between two conceptualizations of client motivation. Hallgren K.A., Moyers T.B., p. 1261-1269.
• Associations between drinking motives and changes in adolescents' alcohol consumption: a full cross-lagged panel study. Schelleman-Offermans K., Kuntsche E., Knibbe R.A., p. 1270-1278.
• Effects of major depression on crack use and arrests among women in drug court. Johnson J.E., O'Leary C.C., Striley C.W., Abdallah A.B., Bradford S., Cottler L.B., p. 1279-1286.
• Drug violations and aviation accidents: findings from the US mandatory drug testing programs. Li G., Baker S.P., Zhao Q., Brady J.E., Lang B.H., Rebok G.W., et al., p. 1287-1292.
• Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Morefield K.M., Keane M., Felgate P., White J.M., Irvine R.J., p. 1293-1300.
• Deviant socialization mediates transmissible and contextual risk on cannabis use disorder development: a prospective study. Tarter R.E., Fishbein D., Kirisci L., Mezzich A., Ridenour T., Vanyukov M., p. 1301-1308.
• Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Everly J.J., Defulio A., Koffarnus M.N., Leoutsakos J.M., Donlin W.D., Aklin W.M., et al., p. 1309-1318.
• Prescribing of smoking cessation medication in England since the introduction of varenicline. Langley T.E., Huang Y., McNeill A., Coleman T., Szatkowski L., Lewis S., p. 1319-1324.
• Relative performance of common biochemical indicators in detecting cigarette smoking. Marrone G.F., Shakleya D.M., Scheidweiler K.B., Singleton E.G., Huestis M.A., Heishman S.J., p. 1325-1334.
• Prospective predictors of quitting behaviours among adult smokers in six cities in China: findings from the International Tobacco Control (ITC) China Survey. Li L., Feng G., Jiang Y., Yong H.H., Borland R., Fong G.T., p. 1335-1345.
• Does the introduction of comprehensive smoke-free legislation lead to a decrease in population smoking prevalence? Bajoga U., Lewis S., McNeill A., Szatkowski L., p. 1346-1354.
• Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. Unger A., Jagsch R., Jones H., Arria A., Leitich H., Rohrmeister K., et al., p. 1355-1362.
• Bruce rounsaville (1949-2011). Carroll K.M., p. 1363-1364.
• Residual neurocognitive features of ecstasy use: a re-interpretation of halpern et al. (2011) consistent with serotonergic neurotoxicity. Parrott A.C., p. 1365-1268.
• Comment on halpern et al. (2011). Fisk J.E., Murphy P.N., Montgomery C., Wareing M., p. 1368-1369.
• 'Ecstasy use, by itself, does not result in residual neurotoxicity'- a powerful argument? Rodgers J., Buchanan T., Heffernan T., Ling J., Scholey A., p. 1369-1370.
• Reply to parrott (2011), fisk et al. (2011) and rodgers et al. (2011). Halpern J.H., Sherwood A.R., Hudson J.I., Gruber S., Kozin D., Pope H.G., Jr., p. 1370-1372.